english

Liste des publications

Cottu P, D'Hondt V, Dureau S, Lerebours F, Desmoulins I, Heudel PE, Duhoux FP, Levy C, Mouret-Reynier MA, Dalenc F, Frenel JS, Jouannaud C, Venat-Bouvet L, Nguyen S, Ferrero JM, Canon JL, Grenier J, Callens C, Gentien D, Lemonnier J, Vincent-Salomon A, Delaloge S. Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer. Ann Oncol. 2018 Dec 1;29(12):2334-2340.

 

Oza AM, Matulonis UA, Malander S, Hudgens S, Sehouli J, Del Campo JM, Berton-Rigaud D, Banerjee S, Scambia G, Berek JS, Lund B, Tinker AV, Hilpert F, Vázquez IP, D'Hondt V, Benigno B, Provencher D, Buscema J, Agarwal S, Mirza MR.

Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2018 Aug;19(8):1117-1125.

 

 

Solassol J, Quantin X, Larrieux M, Senal R, Audran P, Grand D, Mangé A, Diamandis EP, Vendrell JA. Comparison of five cell-free DNA isolation methods to detect the EGFR T790M mutation in plasma samples of patients with lung cancer. Clin Chem Lab Med. 2018 Aug 28;56(9):e243-e246.

 

 

Vendrell JA, Vilquin P, Larrieux M, Van Goethem C, Solassol J. Benchmarking of Amplicon-Based Next-Generation Sequencing Panels Combined with Bioinformatics Solutions for Germline BRCA1 and BRCA2 Alteration Detection. J Mol Diagn. 2018 Nov;20(6):754-764.

 

 

Kurtz JE, D'Hondt V, Lécuru F, Lhommé C. Prise en charge du cancer du col de l’utérus métastatique et/ou en rechute. Bull Cancer. 2017 May;104 Suppl

1:S39-S42.

https://www.ncbi.nlm.nih.gov/pubmed/28625314

 

Leconet W, Chentouf M, du Manoir S, Chevalier C, Sirvent A, Aït-Arsa I, Busson

M, Jarlier M, Radosevic-Robin N, Theillet C, Chalbos D, Pasquet JM, Pèlegrin A,

Larbouret C, Robert B. Therapeutic Activity of Anti-AXL Antibody against

Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis. Clin

Cancer Res. 2017 Jun 1;23(11):2806-2816.

https://www.ncbi.nlm.nih.gov/pubmed/27923843

 

Vendrell JA, Grand D, Rouquette I, Costes V, Icher S, Selves J, Larrieux M,

Barbe A, Brousset P, Solassol J. High-throughput detection of clinically

targetable alterations using next-generation sequencing. Oncotarget. 2017 Jun

20;8(25):40345-40358.

https://www.ncbi.nlm.nih.gov/pubmed/28404952

 

Shi L, Gehin T, Chevolot Y, Souteyrand E, Mangé A, Solassol J, Laurenceau E.

Anti-heat shock protein autoantibody profiling in breast cancer using customized

protein microarray. Anal Bioanal Chem. 2016 Feb;408(5):1497-506.

https://www.ncbi.nlm.nih.gov/pubmed/26715250

 

Solassol J, Vendrell J, Märkl B, Haas C, Bellosillo B, Montagut C, Smith M,

O'Sullivan B, D'Haene N, Le Mercier M, Grauslund M, Melchior LC, Burt E, Cotter

F, Stieber D, Schmitt FL, Motta V, Lauricella C, Colling R, Soilleux E, Fassan M,

Mescoli C, Collin C, Pagès JC, Sillekens P. Multi-Center Evaluation of the Fully

Automated PCR-Based Idylla™ KRAS Mutation Assay for Rapid KRAS Mutation Status

Determination on Formalin-Fixed Paraffin-Embedded Tissue of Human Colorectal

Cancer. PLoS One. 2016 Sep 29;11(9):e0163444.

https://www.ncbi.nlm.nih.gov/pubmed/27685259

 

Valleix S, Verona G, Jourde-Chiche N, Nédelec B, Mangione PP, Bridoux F, Mangé

A, Dogan A, Goujon JM, Lhomme M, Dauteuille C, Chabert M, Porcari R, Waudby CA,

Relini A, Talmud PJ, Kovrov O, Olivecrona G, Stoppini M, Christodoulou J, Hawkins

PN, Grateau G, Delpech M, Kontush A, Gillmore JD, Kalopissis AD, Bellotti V. D25V

apolipoprotein C-III variant causes dominant hereditary systemic amyloidosis and

confers cardiovascular protective lipoprotein profile. Nat Commun. 2016 Jan

21;7:10353.

https://www.ncbi.nlm.nih.gov/pubmed/26790392

 

D'Hondt V, Goffin F, Roca L, Dresse D, Leroy C, Kerger J, Cordier L, de Forges

H, Veys I, Liberale G. Interval Cytoreductive Surgery and Hyperthermic

Intraperitoneal Chemotherapy in First-Line Treatment for Advanced Ovarian

Carcinoma: A Feasibility Study. Int J Gynecol Cancer. 2016 Jun;26(5):912-7.

https://www.ncbi.nlm.nih.gov/pubmed/27051055

 

Jacot W, Pons E, Frenel JS, Guiu S, Levy C, Heudel PE, Bachelot T, D'Hondt V,

Darlix A, Firmin N, Romieu G, Thezenas S, Dalenc F. Efficacy and safety of

trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with

brain metastases. Breast Cancer Res Treat. 2016 Jun;157(2):307-318.

https://www.ncbi.nlm.nih.gov/pubmed/27167986

 

Jacot W, Firmin N, Roca L, Topart D, Gallet S, Durigova A, Mirr S, Abach L,

Pouderoux S, D'Hondt V, Bleuse JP, Lamy PJ, Romieu G. Impact of a tailored oral

vitamin D supplementation regimen on serum 25-hydroxyvitamin D levels in early

breast cancer patients: a randomized phase III study. Ann Oncol. 2016

Jul;27(7):1235-41.

https://www.ncbi.nlm.nih.gov/pubmed/27029707

 

Ignatiadis M, Zardavas D, Lemort M, Wilke C, Vanderbeeken MC, D'Hondt V, De

Azambuja E, Gombos A, Lebrun F, Dal Lago L, Bustin F, Maetens M, Ameye L, Veys I,

Michiels S, Paesmans M, Larsimont D, Sotiriou C, Nogaret JM, Piccart M, Awada A.

Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in

Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative

Breast Cancer. PLoS One. 2016 Jul 25;11(7):e0154009.

https://www.ncbi.nlm.nih.gov/pubmed/27454930

 

Bach AS, Derocq D, Laurent-Matha V, Montcourrier P, Sebti S, Orsetti B, 

Theillet C, Gongora C, Pattingre S, Ibing E, Roger P, Linares LK, Reinheckel T,

Meurice G, Kaiser FJ, Gespach C, Liaudet-Coopman E. Nuclear cathepsin D enhances

TRPS1 transcriptional repressor function to regulate cell cycle progression and

transformation in human breast cancer cells. Oncotarget. 2015 Sep

29;6(29):28084-103.

https://www.ncbi.nlm.nih.gov/pubmed/26183398

 

Despierre E, Vergote I, Anderson R, Coens C, Katsaros D, Hirsch FR, Boeckx B,

Varella-Garcia M, Ferrero A, Ray-Coquard I, Berns EM, Casado A, Lambrechts D,

Jimeno A; European Organisation for Research and Treatment of

Cancer-Gynaecological Cancer Group (EORTC-GCG); Groupe d’Investigateurs Nationaux

pour les Etudes des Cancers de l’Ovaire (GINECO); Austrian Arbeitsgemeinschaft

für Gynäkologische Onkologie (A-AGO); National Cancer Research Institute (NCRI);

Australia New Zealand Gynaecological Oncology Group (ANZGOG); Mario Negri

Gynecologic Oncology group (MaNGO). Epidermal Growth Factor Receptor (EGFR)

Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus

Observation in Ovarian Cancer Patients with No Evidence of Disease Progression

after First-Line Platinum-Based Chemotherapy. Target Oncol. 2015

Dec;10(4):583-96.

https://www.ncbi.nlm.nih.gov/pubmed/26004768

 

Frouin E, Guillot B, Larrieux M, Tempier A, Boulle N, Foulongne V, Girard C,

Costes V, Solassol J. Cutaneous epithelial tumors induced by vemurafenib involve

the MAPK and Pi3KCA pathways but not HPV nor HPyV viral infection. PLoS One. 2014

Oct 31;9(10):e110478.

https://www.ncbi.nlm.nih.gov/pubmed/25360634

 

Bhardwaj D, Náger M, Visa A, Sallán MC, Coopman PJ, Cantí C, Herreros J. Phosphorylated Tyr142 β-catenin localizes to centrosomes and is regulated by Syk. J Cell Biochem. 2017 Dec 12. doi: 10.1002 /jcb.26571. [Epub ahead of print]

 

Vendrell JA, Taviaux S, Béganton B, Godreuil S, Audran P, Grand D, Clermont E, Serre I, Szablewski V, Coopman P, Mazières J, Costes V, Pujol JL, Brousset P, Rouquette I, Solassol J. Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches. Sci Rep. 2017 Oct 2;7(1):12510. doi: 10.1038/s41598- 017-12679-8.

 

Mueller SC, Coopman PJ  (2017). Syk Tyrosine Kinase. In: Schwab M (Ed.) Encyclopedia of Cancer, 4 th edition, Springer-Verlag Berlin Heidelberg, Vol. 1, 4424- 4427.

 

Naldi A, Larive RM, Czerwinska U, Urbach S, Montcourrier P, Roy C, Solassol J, Freiss G, Coopman PJ, Radulescu O. Reconstruction and signal propagation analysis of the Syk signaling network in breast cancer cells. PLoS Comput Biol. 2017 Mar 17;13(3):e1005432. doi: 10.1371/journal.pcbi.1005432. [Epub ahead of print]

 

Vendrell JA, Mau-Them FT, Béganton B, Godreuil S, Coopman P, Solassol J. Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient Management. Int J Mol Sci. 2017 Jan 29;18(2). pii: E264. doi: 10.3390/ijms18020264. Review.

 

Belguise K, Cherradi S, Sarr A, Boissière F, Boulle N, Simony-Lafontaine J, Choesmel-Cadamuro V, Wang X, Chalbos D. PKCθ-induced phosphorylations control the ability of Fra-1 to stimulate gene expression and cancer cell migration. Cancer Lett. 2016 Nov 2. pii: S0304- 3835 (16)30669-3. doi: 10.1016/j. canlet.2016.10.038. [Epub ahead of print]

 

Frouin E, Maudelonde T, Senal R, Larrieux M, Costes V, Godreuil S, Vendrell JA, Solassol J. Comparative Methods to Improve the Detection of BRAF V600 Mutations in Highly Pigmented Melanoma Specimens. PLoS One. 2016 Jul 28;11(7):e0158698. eCollection 2016.

 

Mangé A, Dimitrakopoulos L, Soosaipillai A, Coopman P, Diamandis EP, Solassol J..An integrated cell line-based discovery strategy identified follistatin and kallikrein 6 as serum biomarker candidates of breast carcinoma. J Proteomics. J Proteomics. 2016 May 7. [Epub ahead of print]

 

Coopman P, Djiane A. Adherens Junction and E-Cadherin complex regulation by epithelial polarity. Cell Mol Life Sci. 2016 May 5. [Epub ahead of print

 

Bach AS, Derocq D, Laurent-Matha V, Montcourrier P, Sebti S, Orsetti B, Theillet C, Gongora C, Pattingre S, Ibing E, Roger P, Linares LK, Reinheckel T, Meurice G, Kaiser FJ, Gespach C, Liaudet-Coopman E. Nuclear cathepsin D enhances TRPS1 transcriptional repressor function to regulate cell cycle progression and transformation in human breast cancer cells. Oncotarget. 2015 Jun 27. [Epub ahead of print].

 

Cayrefourcq L, Mazard T, Joosse S, Solassol J, Ramos J, Assenat E, Schumacher U, Costes V, Maudelonde T, Pantel K, Alix-Panabières C  Establishment and characterization of a cell line from human circulating colon  Cancer cells.Cancer Res. 2015 Mar 1;75(5):892-901

 

Bourgier C, Lacombe J, Solassol J, Mange A, Pèlegrin A, Ozsahin M, Azria D. Late side-effects after curative intent radiotherapy: Identification of hypersensitive patients for personalized strategy.
Bourgier C, Lacombe J, Solassol J, Mange A, Pèlegrin A, Ozsahin M, Azria D. Crit Rev Oncol Hematol. 2015 Mar;93(3):312-9. Epub 2014 Nov 22. Review.

 

Mourah S, Denis MG, Narducci FE, Solassol J, Merlin JL, Sabourin JC, Scoazec JY, Ouafik L, Emile JF, Heller R, Souvignet C, Bergougnoux L, Merlio JP. Detection of BRAF V600 mutations in melanoma: evaluation of concordance between the Cobas® 4800 BRAF V600 mutation test and the methods used in French National Cancer Institute (INCa) platforms in a real-life setting.
PLoS One. 2015 Mar 19;10(3):e0120232.  eCollection 2015.

 

Vilquin P, Donini CF, Villedieu M, Grisard E, Corbo L, Bachelot T, Vendrell JA, Cohen PA. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer. Breast Cancer Res. 2015 Jan 30;17(1):13.

 

Larive RM, Moriggi G, Menacho-Márquez M, Cañamero M, de Álava E, Alarcón B, Dosil M, Bustelo XR. Contribution of the R-Ras2 GTP-binding protein to primary breast tumorigenesis and late-stage metastatic disease. Nat Commun. 2014 May 14;5:3881.

 

Lacombe J, Mange A, Bougnoux AC, Prassas I, Solassol J: A multiparametric serum marker panel as a complementary test to mammography for the diagnosis of node-negative early-stage breast cancer and DCIS in young women.

Cancer Epidemiol Biomarkers Prev 2014, 23(9):1834-1842

 

Lacombe J, Mange A, Jarlier M, Bascoul-Mollevi C, Rouanet P, Lamy PJ, Maudelonde T, Solassol J: Identification and validation of new autoantibodies for the diagnosis of DCIS and node negative early-stage breast cancers. Int J Cancer 2013, 132(5):1105-1113

 

Vilquin P, Villedieu M, Grisard E, Ben Larbi S, Ghayad SE, Heudel PE, Bachelot T, Corbo L, Treilleux I, Vendrell JA, Cohen PA.Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor. Int J Cancer. 2013 Oct 1;133(7):1589-602.

 

Lacombe J, Azria D, Mange A, Solassol J: Proteomic approaches to identify biomarkers predictive of radiotherapy outcomes. Expert Rev Proteomics 2013, 10(1):33-42

 

Belguise K, Milord S, Galtier F, Moquet-Torcy G, Piechaczyk M, Chalbos D. The PKCθ pathway participates in the aberrant accumulation of Fra-1 protein in invasive ER-negative breast cancer cells. Oncogene. 2012 Nov 22;31(47):4889-97. doi: 10.1038/onc.2011.659.

 

Larive RM, Abad A, Cardaba CM, Hernández T, Cañamero M, de Álava E, Santos E, Alarcón B, Bustelo XR. The Ras-like protein R-Ras2/TC21 is important for proper mammary gland development. Mol Biol Cell. 2012 Jun;23(12):2373-87.

 

Bougnoux A, Mange A, Solassol J: Proteomic analysis of differently archived breast cancer tissues. Cancer genomics & proteomics 2012, 9(2):93-99

 

Romagnoli M, Belguise K, Yu Z, Wang X, Landesman-Bollag E, Seldin DC, Chalbos D, Barillé-Nion S, Jézéquel P, Seldin ML, Sonenshein GE. Epithelial-to-mesenchymal transition induced by TGF-β1 is mediated by Blimp-1-dependent repression of BMP-5. Cancer Res. 2012; 72(23); 6268–78.

 

Hoskins P, Vergote I, Cervantes A, Tu D, Stuart G, Zola P, Poveda A, Provencher D, Katsaros D, Ojeda B, Ghatage P, Grimshaw R, Casado A, Elit L, Mendiola C, Sugimoto A, D'Hondt V, Oza A, Germa JR, Roy M, Brotto L, Chen D, and Eisenhauer EA  Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel. J Natl Cancer Inst, 2010 102, 1547-1556

 

Desmetz C, Mange A, Maudelonde T, Solassol J: Autoantibody signatures: progress and perspectives for early cancer detection. J Cell Mol Med 2011.Oct;15(10):2013-24

 

Freiss G, Chalbos D. PTPN13/PTPL1: An Important Regulator of Tumor Aggressiveness. Anticancer Agents Med Chem. 2011 Jan 1;11(1):78-88.

 

Solassol J, Rouanet P, Lamy PJ, Allal C, Favre G, Maudelonde T, Mange A: Serum protein signature may improve detection of ductal carcinoma in situ of the breast. Oncogene 2010, 29(4):550-560

 

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés